```
Connecting via Winsock to STN


Welcome to STN International!  Enter x:x

LOGINID:ssspta1653hxp

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2           "Ask CAS" for self-help around the clock
 NEWS  3  JUL 12   BEILSTEIN enhanced with new display and select options,
                   resulting in a closer connection to BABS
 NEWS  4  AUG 02   IFIPAT/IFIUDB/IFICDB reloaded with new search and display
                   fields
 NEWS  5  AUG 02   CAplus and CA patent records enhanced with European and Japan
                   Patent Office Classifications
 NEWS  6  AUG 02   The Analysis Edition of STN Express with Discover!
                   (Version 7.01 for Windows) now available
 NEWS  7  AUG 27   BIOCOMMERCE: Changes and enhancements to content coverage
 NEWS  8  AUG 27   BIOTECHABS/BIOTECHDS: Two new display fields added for legal
                   status data from INPADOC
 NEWS  9  SEP 01   INPADOC: New family current-awareness alert (SDI) available
 NEWS 10  SEP 01   New pricing for the Save Answers for SciFinder Wizard within
                   STN Express with Discover!
 NEWS 11  SEP 01   New display format, HITSTR, available in WPIDS/WPINDEX/WPIX
 NEWS 12  SEP 27   STANDARDS will no longer be available on STN
 NEWS 13  SEP 27   SWETSCAN will no longer be available on STN
 NEWS 14  OCT 28   KOREAPAT now available on STN

 NEWS EXPRESS  OCTOBER 29 CURRENT WINDOWS VERSION IS V7.01A, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 11:14:23 ON 10 NOV 2004

=> file medline, uspatful, ceaba, biosis, biotechds, wpids, embase, dgene, hcaplus,
fsta, jicst, wpix, promt, biobusiness, scisearch
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.42       0.42
```

```
FILE 'MEDLINE' ENTERED AT 11:15:18 ON 10 NOV 2004

FILE 'USPATFULL' ENTERED AT 11:15:18 ON 10 NOV 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CEABA-VTB' ENTERED AT 11:15:18 ON 10 NOV 2004
COPYRIGHT (c) 2004 DECHEMA eV

FILE 'BIOSIS' ENTERED AT 11:15:18 ON 10 NOV 2004
Copyright (c) 2004 The Thomson Corporation.

FILE 'BIOTECHDS' ENTERED AT 11:15:18 ON 10 NOV 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'WPIDS' ENTERED AT 11:15:18 ON 10 NOV 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'EMBASE' ENTERED AT 11:15:18 ON 10 NOV 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'DGENE' ENTERED AT 11:15:18 ON 10 NOV 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'HCAPLUS' ENTERED AT 11:15:18 ON 10 NOV 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'FSTA' ENTERED AT 11:15:18 ON 10 NOV 2004
COPYRIGHT (C) 2004 International Food Information Service

FILE 'JICST-EPLUS' ENTERED AT 11:15:18 ON 10 NOV 2004
COPYRIGHT (C) 2004 Japan Science and Technology Agency (JST)

FILE 'WPIX' ENTERED AT 11:15:18 ON 10 NOV 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'PROMT' ENTERED AT 11:15:18 ON 10 NOV 2004
COPYRIGHT (C) 2004 Gale Group. All rights reserved.

FILE 'BIOBUSINESS' ENTERED AT 11:15:18 ON 10 NOV 2004
Copyright (c) 1998 The Thomson Corporation.

FILE 'SCISEARCH' ENTERED AT 11:15:18 ON 10 NOV 2004
Copyright (c) 2004 The Thomson Corporation.

=> s (factor VIII-vWF-complex)
L1          98 (FACTOR VIII-VWF-COMPLEX)

=> s l1 and specific activity
  10 FILES SEARCHED...
L2          24 L1 AND SPECIFIC ACTIVITY

=> s l1 and vWF activity
L3          13 L1 AND VWF ACTIVITY

=> d l3 ti abs ibib tot

L3   ANSWER 1 OF 13     MEDLINE on STN
TI   Factor VIII, von Willebrand factor and the risk of major ischaemic heart
     disease in the Caerphilly Heart Study.
AB   The relationships of three measurements of the factor VIII/von Willebrand
     factor (VWF) complex (factor VIII activity, FVIIIc (one-stage assay); VWF
```

antigen, VWF Ag (ELISA); and **VWF activity**, VWF act, measured by a recently-developed ELISA) to major ischaemic heart disease (IHD) events were studied in 1997 men aged 49-65 years, in the second phase of the Caerphilly Heart Study. These variables were related using logistic regression analysis to myocardial infarction or IHD death, which occurred in 129 men during an average follow-up period of 61 months. All three measurements were highly correlated (r = 0.63-0.77), and each was significantly associated with incident major IHD on univariate analyses (relative odds in highest fifth compared to lowest fifth, 1.68-1.90; P = 0.028-0.006) and on multivariate analyses adjusting for major IHD risk factors and for baseline IHD. Neither FVIIIc nor VWF act was significantly related to incident IHD following adjustment for VWF Ag. We therefore suggest that the associations between these three measurements of the **factor VIII/VWF complex** and incident IHD might have at least three explanations: VWF Ag is a marker of arterial endothelial disturbance; VWF act promotes platelet adhesion/aggregation and hence the platelet component of arterial thrombosis; and FVIIIc promotes fibrin formation and hence the fibrin component of arterial thrombosis.

ACCESSION NUMBER: 1999250512 MEDLINE
DOCUMENT NUMBER: PubMed ID: 10233372
TITLE: Factor VIII, von Willebrand factor and the risk of major ischaemic heart disease in the Caerphilly Heart Study.
AUTHOR: Rumley A; Lowe G D; Sweetnam P M; Yarnell J W; Ford R P
CORPORATE SOURCE: University Department of Medicine, Glasgow Royal Infirmary, Glasgow, UK.
SOURCE: British journal of haematology, (1999 Apr) 105 (1) 110-6. Journal code: 0372544. ISSN: 0007-1048.
PUB. COUNTRY: ENGLAND: United Kingdom
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199906
ENTRY DATE: Entered STN: 19990618
Last Updated on STN: 19990618
Entered Medline: 19990610

L3 ANSWER 2 OF 13 USPATFULL on STN
TI Haemostatically active preparation containing vwf and method for the production thereof
AB A process for preparing a hemostatically active preparation containing von Willebrand factor (vWF) from a fraction of human plasma by chromatographic purification of a vWF-containing plasma fraction on an anion-exchange material which has the anion-exchanging groups on grafted polymeric structures (tentacle materials), collecting a vWF-containing fraction, followed by purification of said fraction using gel permeation to prepare a purified thermally stable vWF-containing preparation; and heating the preparation for inactivating viruses.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:200928 USPATFULL
TITLE: Haemostatically active preparation containing vwf and method for the production thereof
INVENTOR(S): Josic, Djuro, Vienna, AUSTRIA
Stadler, Monika, Wienerherberg, AUSTRIA
Gruber, Gerhard, Vienna, AUSTRIA

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003138913	A1	20030724	
APPLICATION INFO.:	US 2002-257375	A1	20021017	(10)
	WO 2001-EP3819		20010404	

	NUMBER	DATE

PRIORITY INFORMATION:	EP 2000-108430	20000418
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	JACOBSON HOLMAN PLLC, 400 SEVENTH STREET N.W., SUITE 600, WASHINGTON, DC, 20004	
NUMBER OF CLAIMS:	15	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Page(s)	
LINE COUNT:	222	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 3 OF 13 USPATFULL on STN

TI Purification of von-Willebrand factor by cation exchanger chromatography

AB Disclosed are a method of recovering vWF in which vWF at a low salt concentration is bound to a cation exchanger and vWF having a high specific activity is recovered by fractionated elution, as well as a preparation having purified vWF obtainable by this method.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2002:268871 USPATFULL			
TITLE:	Purification of von-Willebrand factor by cation exchanger chromatography			
INVENTOR(S):	Fischer, Bernhard, Vienna, AUSTRIA Schonberger, Oyvind L., Vienna, AUSTRIA Mitterer, Artur, Mannsdorf, AUSTRIA Fiedler, Christian, Vienna, AUSTRIA Dorner, Friedrich, Vienna, AUSTRIA Eibl, Johann, Vienna, AUSTRIA			
PATENT ASSIGNEE(S):	Baxter Aktiengesellschaft, Vienna, AUSTRALIA (non-U.S. corporation)			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6465624	B1	20021015	
	WO 9838219		19980903	
APPLICATION INFO.:	US 1999-367460		19991021	(9)
	WO 1998-AT34		19980218	
			19991021	PCT 371 date
	NUMBER		DATE	
PRIORITY INFORMATION:	AT 1997-337		19970227	
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	GRANTED			
PRIMARY EXAMINER:	Carlson, Karen Cochrane			
ASSISTANT EXAMINER:	Robinson, Hope A.			
LEGAL REPRESENTATIVE:	Townsend and Townsend and Crew LLP			
NUMBER OF CLAIMS:	22			
EXEMPLARY CLAIM:	1			
NUMBER OF DRAWINGS:	3 Drawing Figure(s); 3 Drawing Page(s)			
LINE COUNT:	726			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 4 OF 13 USPATFULL on STN

TI Method of chromatographically purifying or fractionating, respectively, von Willebrand factor from a VWF-containing starting material

AB Disclosed is a method of chromatographically purifying or fractionating, respectively, von Willebrand factor (vWF) from a vWF-containing starting material, comprising the following steps:

adsorbing the vWF from the starting material on avid collagen immobilized on a carrier,

separating the non-adsorbed portion and, optionally, washing the carrier,

eluting the vWF from immobilized collagen, and

recovering the purified vWF, as well as a pharmaceutical preparation comprising biologically active vWF which is bound to collagen in a stable manner.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2002:160854 USPATFULL			
TITLE:	Method of chromatographically purifying or fractionating, respectively, von Willebrand factor from a VWF-containing starting material			
INVENTOR(S):	Siekmann, Juergen, Vienna, AUSTRIA Turecek, Peter, Klosterneuburg, AUSTRIA Schwarz, Hans-Peter, Vienna, AUSTRIA Eibl, Johann, Vienna, AUSTRIA Fischer, Bernhard, Vienna, AUSTRIA Mitterer, Artur, Mannsdorf, AUSTRIA Dorner, Friedrich, Vienna, AUSTRIA			
PATENT ASSIGNEE(S):	Baxter Aktiengesellschaft, Vienna, AUSTRIA (non-U.S. corporation)			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6414125	B1	20020702	
	WO 9833820		19980806	
APPLICATION INFO.:	US 1999-355865		19991021	(9)
	WO 1998-AT20		19980130	
			19991021	PCT 371 date
	NUMBER		DATE	
PRIORITY INFORMATION:	AT 1997-176		19970204	
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	GRANTED			
PRIMARY EXAMINER:	Carlson, Karen Cochrane			
ASSISTANT EXAMINER:	Robinson, Hope A.			
LEGAL REPRESENTATIVE:	Townsend and Townsend and Crew LLP			
NUMBER OF CLAIMS:	47			
EXEMPLARY CLAIM:	1			
NUMBER OF DRAWINGS:	1 Drawing Figure(s); 1 Drawing Page(s)			
LINE COUNT:	659			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 5 OF 13 USPATFULL on STN

TI Method for purifying factor vWF-complex by means of cation exchange chromatography

AB There is disclosed a method of recovering **factor VIII /vWF-complex** which is characterized in that **factor VIII/vWF-complex** from a protein solution is bound to a cation exchanger and is recovered by step-wise elution of **factor VIII/vWF-complex**, which particularly contains high-molecular vWF multimers, as well as a **factor VIII/vWF-complex** obtainable by means of cation exchange chromatography.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2002:112884 USPATFULL
TITLE:	Method for purifying factor vWF-complex by means of cation exchange chromatography
INVENTOR(S):	Mitterer, Artur, Mannsdorf, AUSTRIA Fischer, Bernhard, Vienna, AUSTRIA

Schonberger, Oyvind L., Vienna, AUSTRIA
Thomas-Urban, Kathrin, Freiburg, GERMANY, FEDERAL REPUBLIC OF
Dorner, Friedrich, Vienna, AUSTRIA
Eibl, Johann, Vienna, AUSTRIA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002058625	A1	20020516
APPLICATION INFO.:	US 2001-3621	A1	20011102 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 2000-367459, filed on 8 May 2000, PENDING A 371 of International Ser. No. WO 1998-AT43, filed on 27 Feb 1998, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	AT 1997-338	19970227

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Page(s)
LINE COUNT: 663
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 6 OF 13 USPATFULL on STN
TI Stable **factor VIII / vWF-complex**
AB There are disclosed a stable **factor VIII/vWF -complex**, particularly comprising high-molecular vWF multimers, being free from low-molecular vWF molecules and from proteolytic vWF degradation products, as well as a method of producing this complex.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2002:43190 USPATFULL
TITLE: Stable **factor VIII / vWF-complex**
INVENTOR(S): Fischer, Bernhard, Vienna, AUSTRIA
Mitterer, Artur, Mannsdorf, AUSTRIA
Dorner, Friedrich, Vienna, AUSTRIA
Eibl, Johann, Vienna, AUSTRIA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002025556	A1	20020228
APPLICATION INFO.:	US 2001-849484	A1	20010507 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1998-142768, filed on 6 Nov 1998, GRANTED, Pat. No. US 6228613 A 371 of International Ser. No. WO 1997-AT55, filed on 13 Mar 1997, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	AT 1996-494	19960315

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HELLER EHRMAN WHITE & MCAULIFFE LLP, 1666 K STREET,NW, SUITE 300, WASHINGTON, DC, 20006
NUMBER OF CLAIMS: 43
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 9 Drawing Page(s)
LINE COUNT: 1141

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 7 OF 13 USPATFULL on STN
TI Stable factor VIII/von Willebrand factor complex
AB There are disclosed a stable **factor VIII/vWF -complex**, particularly comprising high-molecular vWF multimers, being free from low-molecular vWF molecules and from proteolytic vWF degradation products, as well as a method of producing this complex.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2001:67424 USPATFULL		
TITLE:	Stable factor VIII/von Willebrand factor complex		
INVENTOR(S):	Fischer, Bernhard, Vienna, Austria Mitterer, Artur, Mannsdorf, Austria Dorner, Friedrich, Vienna, Austria Eibl, Johann, Vienna, Austria		
PATENT ASSIGNEE(S):	Baxter Aktiengesellschaft, Vienna, Austria (non-U.S. corporation)		

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6228613	B1	20010508	
	WO 9734930		19970925	
APPLICATION INFO.:	US 1998-142768		19981106	(9)
	WO 1997-AT55		19970313	
			19981106	PCT 371 date
			19981106	PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	AT 1996-494	19960315

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Carlson, Karen Cochrane
ASSISTANT EXAMINER:	Robinson, Hope A.
LEGAL REPRESENTATIVE:	Heller Ehrman White & McAuliffe
NUMBER OF CLAIMS:	40
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	9 Drawing Figure(s); 9 Drawing Page(s)
LINE COUNT:	1098

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 8 OF 13 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
TI Factor VIII, von Willebrand factor and the risk of major ischaemic heart disease in the Caerphilly Heart Study.
AB The relationships of three measurements of the factor VIII/von Willebrand factor (VWF) complex (factor VIII activity. FVIIIc (one-stage assay); VWF antigen, VWF Ag (ELISA); and **VWF activity**, VWF act, measured by a recently-developed ELISA) to major ischaemic heart disease (IHD) events were studied in 1997 men aged 49-65 years, in the second phase of the Caerphilly Heart Study. These variables were related using logistic regression analysis to myocardial infarction or IHD death, which occurred in 129 men during an average follow-up period of 61 months. All three measurements were highly correlated (r=0.63-0.77), and each was significantly associated with incident major IHD on univariate analyses (relative odds in highest fifth compared to lowest fifth, 1.68-1.90; P=0.028-0.006) and on multivariate analyses adjusting for major IHD risk factors and for baseline IHD. Neither FVIIIc nor VWF act was significantly related to incident IHD following adjustment for VWF Ag. We therefore suggest that the associations between these three measurements of the **factor VIII/VWF complex** and incident IHD might have at least three explanations: VWF Ag is a marker of

arterial endothelial disturbance; VWF act promotes platelet adhesion/aggregation and hence the platelet component of arterial thrombosis; and FVIIIc promotes fibrin formation and hence the fibrin component of arterial thrombosis.

ACCESSION NUMBER: 1999:261609 BIOSIS
DOCUMENT NUMBER: PREV199900261609
TITLE: Factor VIII, von Willebrand factor and the risk of major ischaemic heart disease in the Caerphilly Heart Study.
AUTHOR(S): Rumley, A.; Lowe, G. D. O. [Reprint author]; Sweetnam, P. M.; Yarnell, J. W. G.; Ford, R. P.
CORPORATE SOURCE: University Department of Medicine, Glasgow Royal Infirmary, 10 Alexandra Parade, Glasgow, G31 2ER, UK
SOURCE: British Journal of Haematology, (April, 1999) Vol. 105, No. 1, pp. 110-116. print.
CODEN: BJHEAL. ISSN: 0007-1048.
DOCUMENT TYPE: Article
LANGUAGE: English
ENTRY DATE: Entered STN: 2 Jul 1999
Last Updated on STN: 2 Jul 1999

L3 ANSWER 9 OF 13 BIOTECHDS COPYRIGHT 2004 THE THOMSON CORP. on STN
TI Recovering high purity Factor-VIII/von Willebrand factor complexes; from plasma by bonding to immobilized monoclonal antibody obtained by hybridoma construction; affinity chromatography
AN 1987-10591 BIOTECHDS
AB Factor-VIII/von Willebrand factor (vWF) complexes for therapeutic use are produced by (a) adsorbing the complex in physiological medium on a monoclonal antibody able to release the complex at pH 8.5-10.5; (b) releasing the complex using an elution medium at that pH having no effect on its function but able to dissociate bonds between monoclonal antibody and the complex, and (c) collecting the purified complex. Preferably, the antibody is linked to a solid adsorbent and is used in several cycles. The monoclonal antibody is derived from a hybridoma obtained by hybridization of mouse X63 myeloma cells and splenocytes from a BALB/c mouse immunized with **Factor-VIII/vWF complex**. The product has both hemophilic A and **VWF activity**, and is obtained with a high degree of purity. (4pp)
ACCESSION NUMBER: 1987-10591 BIOTECHDS
TITLE: Recovering high purity Factor-VIII/von Willebrand factor complexes; from plasma by bonding to immobilized monoclonal antibody obtained by hybridoma construction; affinity chromatography
PATENT ASSIGNEE: Immunotech
PATENT INFO: US 4670543 2 Jun 1987
APPLICATION INFO: US 1985-777335 18 Sep 1985
PRIORITY INFO: FR 1984-14480 18 Sep 1984
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: WPI: 1986-093996 [14]

L3 ANSWER 10 OF 13 WPIDS COPYRIGHT 2004 THE THOMSON CORP on STN
TI Compsns. containing antibodies directed against blood clotting factors - for production of animal models for clotting disorders or for treating clotting disorders.
AN 1997-022856 [03] WPIDS
AB EP 747060 A UPAB: 19970115
Anti-plasma antibody compsn. for the treatment of a mammal is capable of directly or indirectly inhibiting and/or eliminating several blood [clotting] factors.

Also claimed is a mammal with a blood clotting disorder induced by a compsn. as described above.

USE - The compsn. is used for the creation of animal models for clotting factor deficiencies, e.g. haemophilia, especially von

Willebrand-Juergens syndrome. The animal models are useful for evaluating substances for treating clotting disorders. Compsns. containing antibodies directed against von Willebrand factor (vWF) or **factor VIII/vWF complex**, are used for the treatment or prevention of conditions associated with thrombocyte aggregation resulting from abnormal **vWF activity**, e.g. haemolytic uraemic syndrome, adult respiratory distress syndrome or arteriosclerosis. The compsns. can be used for determining the bleeding characteristics of a mammal by inducing bleeding, collecting blood fractions, determining the haemoglobin content of the fractions and determining the cumulative blood loss and/or bleeding kinetics (all claimed).
Dwg.6/7

ACCESSION NUMBER: 1997-022856 [03] WPIDS
DOC. NO. CPI: C1997-007350
TITLE: Compsns. containing antibodies directed against blood clotting factors - for production of animal models for clotting disorders or for treating clotting disorders.
DERWENT CLASS: B04
INVENTOR(S): EIBL, J; SCHWARZ, H P; TURECEK, P
PATENT ASSIGNEE(S): (IMMO) IMMUNO AG
COUNTRY COUNT: 14
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
EP 747060	A2	19961211	(199703)*	GE	18
R: AT BE CH DE DK ES FI FR GB IT LI NL SE					
EP 747060	A3	19970507	(199731)		
AT 9500987	A	19980415	(199820)		
US 5804159	A	19980908	(199843)		
AT 404429	B	19981015	(199846)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
EP 747060	A2	EP 1996-890096	19960604
EP 747060	A3	EP 1996-890096	19960604
AT 9500987	A	AT 1995-987	19950609
US 5804159	A	US 1996-663031	19960607
AT 404429	B	AT 1995-987	19950609

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AT 404429	B Previous Publ.	AT 9500987

PRIORITY APPLN. INFO: AT 1995-987 19950609

L3 ANSWER 11 OF 13 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
TI Factor VIII, von Willebrand factor and the risk of major ischaemic heart disease in the Caerphilly Heart Study.
AB The relationships of three measurements of the factor VIII/von Willebrand factor (VWF) complex (factor VIII activity, FVIIIc (one-stage assay); VWF antigen, VWF Ag (ELISA); and **VWF activity**, VWF act, measured by a recently-developed ELISA) to major ischaemic heart disease (IHD) events were studied in 1997 men aged 49-65 years, in the second phase of the Caerphilly Heart Study. These variables were related using logistic regression analysis to myocardial infarction or IHD death, which occurred in 129 men during an average follow-up period of 61 months. All three measurements were highly correlated (r = 0.63-0.77), and each was significantly associated with incident major IHD on univariate analyses

(relative odds in highest fifth compared to lowest fifth, 1.68-1.90; P=0.028-0.006) and on multivariate analyses adjusting for major IHD risk factors and for baseline IHD. Neither FVIIIc nor VWF act was significantly related to incident IHD following adjustment for VWF Ag. We therefore suggest that the associations between these three measurements of the **factor VIII/VWF complex** and incident IHD might have at least three explanations: VWF Ag is a marker of arterial endothelial disturbance; VWF act promotes platelet adhesion/aggregation and hence the platelet component of arterial thrombosis; and FVIIIc promotes fibrin formation and hence the fibrin component of arterial thrombosis.

ACCESSION NUMBER: 1999150325 EMBASE
TITLE: Factor VIII, von Willebrand factor and the risk of major ischaemic heart disease in the Caerphilly Heart Study.
AUTHOR: Rumley A.; Lowe G.D.O.; Sweetnam P.M.; Yarnell J.W.G.; Ford R.P.
CORPORATE SOURCE: Prof. G.D.O. Lowe, University Department of Medicine, Glasgow Royal Infirmary, 10 Alexandra Parade, Glasgow G31 2ER, United Kingdom
SOURCE: British Journal of Haematology, (1999) 105/1 (110-116). Refs: 24
ISSN: 0007-1048 CODEN: BJHEAL
COUNTRY: United Kingdom
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 017 Public Health, Social Medicine and Epidemiology
018 Cardiovascular Diseases and Cardiovascular Surgery
025 Hematology
LANGUAGE: English
SUMMARY LANGUAGE: English

L3 ANSWER 12 OF 13 WPIX COPYRIGHT 2004 THE THOMSON CORP on STN
TI Compsns. containing antibodies directed against blood clotting factors - for production of animal models for clotting disorders or for treating clotting disorders.
AN 1997-022856 [03] WPIX
AB EP 747060 A UPAB: 19970115
Anti-plasma antibody compsn. for the treatment of a mammal is capable of directly or indirectly inhibiting and/or eliminating several blood [clotting] factors.

Also claimed is a mammal with a blood clotting disorder induced by a compsn. as described above.

USE - The compsn. is used for the creation of animal models for clotting factor deficiencies, e.g. haemophilia, especially von Willebrand-Juergens syndrome. The animal models are useful for evaluating substances for treating clotting disorders. Compsns. containing antibodies directed against von Willebrand factor (vWF) or **factor VIII/vWF complex**, are used for the treatment or prevention of conditions associated with thrombocyte aggregation resulting from abnormal **vWF activity**, e.g. haemolytic uraemic syndrome, adult respiratory distress syndrome or arteriosclerosis. The compsns. can be used for determining the bleeding characteristics of a mammal by inducing bleeding, collecting blood fractions, determining the haemoglobin content of the fractions and determining the cumulative blood loss and/or bleeding kinetics (all claimed).

Dwg.6/7

ACCESSION NUMBER: 1997-022856 [03] WPIX
DOC. NO. CPI: C1997-007350
TITLE: Compsns. containing antibodies directed against blood clotting factors - for production of animal models for clotting disorders or for treating clotting disorders.
DERWENT CLASS: B04
INVENTOR(S): EIBL, J; SCHWARZ, H P; TURECEK, P
PATENT ASSIGNEE(S): (IMMO) IMMUNO AG
COUNTRY COUNT: 14

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
EP 747060	A2	19961211	(199703)*	GE	18
R: AT BE CH DE DK ES FI FR GB IT LI NL SE					
EP 747060	A3	19970507	(199731)		
AT 9500987	A	19980415	(199820)		
US 5804159	A	19980908	(199843)		
AT 404429	B	19981015	(199846)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
EP 747060	A2	EP 1996-890096	19960604
EP 747060	A3	EP 1996-890096	19960604
AT 9500987	A	AT 1995-987	19950609
US 5804159	A	US 1996-663031	19960607
AT 404429	B	AT 1995-987	19950609

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AT 404429	B Previous Publ.	AT 9500987

PRIORITY APPLN. INFO: AT 1995-987 19950609

L3 ANSWER 13 OF 13 SCISEARCH COPYRIGHT (c) 2004 The Thomson Corporation. on STN

TI Factor VIII, von Willebrand factor and the risk of major ischaemic heart disease in the Caerphilly Heart Study

AB The relationships of three measurements of the factor VIII/von Willebrand factor (VWF) complex (factor VIII activity, FVIIIc (one-stage assay); VWF antigen, VWF Ag (ELISA); and **VWF activity**, VWF act, measured by a recently-developed ELISA) to major ischaemic heart disease (IHD) events were studied in 1997 men aged 49-65 years, in the second phase of the Caerphilly Heart Study. These variables were related using logistic regression analysis to myocardial infarction or IHD death, which occurred in 129 men during an average follow-up period of 61 months. All three measurements were highly correlated (r=0.63-0.77), and each was significantly associated with incident major IHD on univariate analyses (relative odds in highest fifth compared to lowest fifth, 1.68-1.90; P=0.028-0.006) and on multivariate analyses adjusting for major IHD risk factors and for baseline IHD. Neither FVIIIc nor VWF act was significantly related to incident IHD following adjustment for VWF Ag. We therefore suggest that the associations between these three measurements of the **factor VIII/VWF complex** and incident IHD might have at least three explanations: VWF Ag is a marker of arterial endothelial disturbance; VWF act promotes platelet adhesion/aggregation and hence the platelet component of arterial thrombosis; and FVIIIc promotes fibrin formation and hence the fibrin component of arterial thrombosis.

ACCESSION NUMBER: 1999:358232 SCISEARCH

THE GENUINE ARTICLE: 192CP

TITLE: Factor VIII, von Willebrand factor and the risk of major ischaemic heart disease in the Caerphilly Heart Study

AUTHOR: Rumley A; Lowe G D O (Reprint); Sweetnam P M; Yarnell J W G; Ford R P

CORPORATE SOURCE: UNIV GLASGOW, GLASGOW ROYAL INFIRM, DEPT MED, 10 ALEXANDRA PARADE, GLASGOW G31 2ER, LANARK, SCOTLAND (Reprint); UNIV GLASGOW, GLASGOW ROYAL INFIRM, DEPT MED, GLASGOW G31 2ER, LANARK, SCOTLAND; LLANDOUGH HOSP, MRC, EPIDEMIOL UNIT S

WALES, PENARTH, S GLAM, WALES; SHIELD DIAGNOST LTD, DUNDEE, SCOTLAND; QUEENS UNIV BELFAST, DIV EPIDEMIOL, BELFAST, ANTRIM, NORTH IRELAND
COUNTRY OF AUTHOR: SCOTLAND; WALES; NORTH IRELAND
SOURCE: BRITISH JOURNAL OF HAEMATOLOGY, (APR 1999) Vol. 105, No. 1, pp. 110-116.
Publisher: BLACKWELL SCIENCE LTD, P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND.
ISSN: 0007-1048.
DOCUMENT TYPE: Article; Journal
FILE SEGMENT: LIFE; CLIN
LANGUAGE: English
REFERENCE COUNT: 24
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

=> d his

(FILE 'HOME' ENTERED AT 11:14:23 ON 10 NOV 2004)

FILE 'MEDLINE, USPATFULL, CEABA-VTB, BIOSIS, BIOTECHDS, WPIDS, EMBASE, DGENE, HCAPLUS, FSTA, JICST-EPLUS, WPIX, PROMT, BIOBUSINESS, SCISEARCH' ENTERED AT 11:15:18 ON 10 NOV 2004
L1 98 S (FACTOR VIII-VWF-COMPLEX)
L2 24 S L1 AND SPECIFIC ACTIVITY
L3 13 S L1 AND VWF ACTIVITY

=> s l1 and factor VIII activity
L4 29 L1 AND FACTOR VIII ACTIVITY

=> s l1 and pharmaceutical preparation
L5 7 L1 AND PHARMACEUTICAL PREPARATION

=> d l7 ti abs ibib tot
L7 NOT FOUND
The L-number entered has not been defined in this session, or it has been deleted. To see the L-numbers currently defined in this session, enter DISPLAY HISTORY at an arrow prompt (=>).

=> s l5 ti abs ibib tot
MISSING OPERATOR L5 TI
The search profile that was entered contains terms or nested terms that are not separated by a logical operator.

=> d l5 ti abs ibib tot

L5 ANSWER 1 OF 7 USPATFULL on STN
TI Method of recovering highly purified vWF or **factor VIII/vWF-complex**
AB A method for purifying **factor VIII/vWF complex** or free vWF by immunoaffinity chromatography in a form suitable for use as a medicament. **Factor VIII/vWF complex** or free vWF is recovered from an immunoaffinity adsorbent by using an eluting agent containing a zwitterionic species. The presence of the zwitterionic species allows for the use of mild conditions throughout the preparation, facilitating retention of molecular integrity, activity, and incorporation of the recovered proteins into pharmaceutical preparations without the need for additional stabilizers or preservatives.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:161896 USPATFULL
TITLE: Method of recovering highly purified vWF or **factor VIII/vWF-**

complex

INVENTOR(S): Mitterer, Artur, Mannsdorf, AUSTRIA
Fiedler, Christian, Vienna, AUSTRIA
Fischer, Bernhard, Vienna, AUSTRIA
Dorner, Friedrich, Vienna, AUSTRIA
Eibl, Johann, Vienna, AUSTRIA

PATENT ASSIGNEE(S): Baxter Aktiengesellschaft, Vienna, AUSTRIA (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6579723	B1	20030617	
	WO 9838218		19980903	
APPLICATION INFO.:	US 1999-367362		19991021	(9)
	WO 1998-AT33		19980218	

	NUMBER	DATE
PRIORITY INFORMATION:	AT 1997-339	19970227

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Le, Long V.
ASSISTANT EXAMINER: Gabel, Gailene R.
LEGAL REPRESENTATIVE: Townsend and Townsend and Crew LLP
NUMBER OF CLAIMS: 51
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 1046
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 2 OF 7 USPATFULL on STN
TI Purification of von-Willebrand factor by cation exchanger chromatography
AB Disclosed are a method of recovering vWF in which vWF at a low salt concentration is bound to a cation exchanger and vWF having a high specific activity is recovered by fractionated elution, as well as a preparation having purified vWF obtainable by this method.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2002:268871 USPATFULL
TITLE: Purification of von-Willebrand factor by cation exchanger chromatography
INVENTOR(S): Fischer, Bernhard, Vienna, AUSTRIA
Schonberger, Oyvind L., Vienna, AUSTRIA
Mitterer, Artur, Mannsdorf, AUSTRIA
Fiedler, Christian, Vienna, AUSTRIA
Dorner, Friedrich, Vienna, AUSTRIA
Eibl, Johann, Vienna, AUSTRIA
PATENT ASSIGNEE(S): Baxter Aktiengesellschaft, Vienna, AUSTRALIA (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6465624	B1	20021015	
	WO 9838219		19980903	
APPLICATION INFO.:	US 1999-367460		19991021	(9)
	WO 1998-AT34		19980218	
			19991021	PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	AT 1997-337	19970227

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Carlson, Karen Cochrane

ASSISTANT EXAMINER: Robinson, Hope A.
LEGAL REPRESENTATIVE: Townsend and Townsend and Crew LLP
NUMBER OF CLAIMS: 22
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 726
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 3 OF 7 USPATFULL on STN
TI Method of chromatographically purifying or fractionating, respectively, von Willebrand factor from a VWF-containing starting material
AB Disclosed is a method of chromatographically purifying or fractionating, respectively, von Willebrand factor (vWF) from a vWF-containing starting material, comprising the following steps:

adsorbing the vWF from the starting material on avid collagen immobilized on a carrier,

separating the non-adsorbed portion and, optionally, washing the carrier,

eluting the vWF from immobilized collagen, and

recovering the purified vWF, as well as a **pharmaceutical preparation** comprising biologically active vWF which is bound to collagen in a stable manner.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2002:160854 USPATFULL
TITLE: Method of chromatographically purifying or fractionating, respectively, von Willebrand factor from a VWF-containing starting material
INVENTOR(S): Siekmann, Juergen, Vienna, AUSTRIA
Turecek, Peter, Klosterneuburg, AUSTRIA
Schwarz, Hans-Peter, Vienna, AUSTRIA
Eibl, Johann, Vienna, AUSTRIA
Fischer, Bernhard, Vienna, AUSTRIA
Mitterer, Artur, Mannsdorf, AUSTRIA
Dorner, Friedrich, Vienna, AUSTRIA
PATENT ASSIGNEE(S): Baxter Aktiengesellschaft, Vienna, AUSTRIA (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6414125	B1	20020702	
	WO 9833820		19980806	
APPLICATION INFO.:	US 1999-355865		19991021	(9)
	WO 1998-AT20		19980130	
			19991021	PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	AT 1997-176	19970204

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Carlson, Karen Cochrane
ASSISTANT EXAMINER: Robinson, Hope A.
LEGAL REPRESENTATIVE: Townsend and Townsend and Crew LLP
NUMBER OF CLAIMS: 47
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 659
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 4 OF 7 USPATFULL on STN
TI Method for purifying factor vWF-complex by means of cation exchange chromatography
AB There is disclosed a method of recovering **factor VIII /vWF-complex** which is characterized in that **factor VIII/vWF-complex** from a protein solution is bound to a cation exchanger and is recovered by step-wise elution of **factor VIII/vWF-complex**, which particularly contains high-molecular vWF multimers, as well as a **factor VIII/vWF-complex** obtainable by means of cation exchange chromatography.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2002:112884 USPATFULL
TITLE:	Method for purifying factor vWF-complex by means of cation exchange chromatography
INVENTOR(S):	Mitterer, Artur, Mannsdorf, AUSTRIA Fischer, Bernhard, Vienna, AUSTRIA Schonberger, Oyvind L., Vienna, AUSTRIA Thomas-Urban, Kathrin, Freiburg, GERMANY, FEDERAL REPUBLIC OF Dorner, Friedrich, Vienna, AUSTRIA Eibl, Johann, Vienna, AUSTRIA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002058625	A1	20020516
APPLICATION INFO.:	US 2001-3621	A1	20011102 (10)

RELATED APPLN. INFO.:	Division of Ser. No. US 2000-367459, filed on 8 May 2000, PENDING A 371 of International Ser. No. WO 1998-AT43, filed on 27 Feb 1998, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	AT 1997-338	19970227

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834
NUMBER OF CLAIMS:	20
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	2 Drawing Page(s)
LINE COUNT:	663

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 5 OF 7 USPATFULL on STN
TI Stable **factor VIII / vWF-complex**
AB There are disclosed a stable **factor VIII/vWF-complex**, particularly comprising high-molecular vWF multimers, being free from low-molecular vWF molecules and from proteolytic vWF degradation products, as well as a method of producing this complex.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2002:43190 USPATFULL
TITLE:	Stable **factor VIII / vWF-complex**
INVENTOR(S):	Fischer, Bernhard, Vienna, AUSTRIA Mitterer, Artur, Mannsdorf, AUSTRIA Dorner, Friedrich, Vienna, AUSTRIA Eibl, Johann, Vienna, AUSTRIA

	NUMBER	KIND	DATE

PATENT INFORMATION:	US 2002025556	A1	20020228
APPLICATION INFO.:	US 2001-849484	A1	20010507 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1998-142768, filed on 6 Nov 1998, GRANTED, Pat. No. US 6228613 A 371 of International Ser. No. WO 1997-AT55, filed on 13 Mar 1997, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	AT 1996-494	19960315

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HELLER EHRMAN WHITE & MCAULIFFE LLP, 1666 K STREET,NW, SUITE 300, WASHINGTON, DC, 20006
NUMBER OF CLAIMS: 43
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 9 Drawing Page(s)
LINE COUNT: 1141
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 6 OF 7 USPATFULL on STN
TI Highly purified factor VIII complex
AB There is disclosed a highly purified complex comprising the components factor VIII and vWF having a specific activity of at least 70, preferably 100 to 300 U factor VIII:C/mg, a stable **pharmaceutical preparation** containing this complex as well as a method of producing the same.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2001:185463 USPATFULL
TITLE: Highly purified factor VIII complex
INVENTOR(S): Schonhofer, Wolfgang, Polten, Austria
Eibl, Johann, Vienna, Austria
Weber, Alfred, Vienna, Austria
Linnau, Yendra, Vienna, Austria
PATENT ASSIGNEE(S): Baxter Aktiengesellschaft, Vienna, Austria (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6307032	B1	20011023	
	WO 9739033		19971023	
APPLICATION INFO.:	US 1998-171121		19981118	(9)
	WO 1997-AT69		19970409	
			19981118	PCT 371 date
			19981118	PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	AT 1996-667	19960412

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Carlson, Karen Cochrane
ASSISTANT EXAMINER: Schnizer, Holly
LEGAL REPRESENTATIVE: Heller Ehrman White & McAuliffe
NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
LINE COUNT: 509
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 7 OF 7 USPATFULL on STN
TI Stable factor VIII/von Willebrand factor complex
AB There are disclosed a stable **factor VIII/vWF -complex**, particularly comprising high-molecular vWF

multimers, being free from low-molecular vWF molecules and from proteolytic vWF degradation products, as well as a method of producing this complex.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2001:67424 USPATFULL			
TITLE:	Stable factor VIII/von Willebrand factor complex			
INVENTOR(S):	Fischer, Bernhard, Vienna, Austria Mitterer, Artur, Mannsdorf, Austria Dorner, Friedrich, Vienna, Austria Eibl, Johann, Vienna, Austria			
PATENT ASSIGNEE(S):	Baxter Aktiengesellschaft, Vienna, Austria (non-U.S. corporation)			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6228613	B1	20010508	
	WO 9734930		19970925	
APPLICATION INFO.:	US 1998-142768		19981106	(9)
	WO 1997-AT55		19970313	
			19981106	PCT 371 date
			19981106	PCT 102(e) date
	NUMBER		DATE	
PRIORITY INFORMATION:	AT 1996-494		19960315	
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	Granted			
PRIMARY EXAMINER:	Carlson, Karen Cochrane			
ASSISTANT EXAMINER:	Robinson, Hope A.			
LEGAL REPRESENTATIVE:	Heller Ehrman White & McAuliffe			
NUMBER OF CLAIMS:	40			
EXEMPLARY CLAIM:	1			
NUMBER OF DRAWINGS:	9 Drawing Figure(s); 9 Drawing Page(s)			
LINE COUNT:	1098			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 11:14:23 ON 10 NOV 2004)

FILE 'MEDLINE, USPATFULL, CEABA-VTB, BIOSIS, BIOTECHDS, WPIDS, EMBASE, DGENE, HCAPLUS, FSTA, JICST-EPLUS, WPIX, PROMT, BIOBUSINESS, SCISEARCH' ENTERED AT 11:15:18 ON 10 NOV 2004

L1	98	S (FACTOR VIII-VWF-COMPLEX)
L2	24	S L1 AND SPECIFIC ACTIVITY
L3	13	S L1 AND VWF ACTIVITY
L4	29	S L1 AND FACTOR VIII ACTIVITY
L5	7	S L1 AND PHARMACEUTICAL PREPARATION

=> d l4 ti abs ibib tot

L4 ANSWER 1 OF 29 MEDLINE on STN

TI Factor VIII, von Willebrand factor and the risk of major ischaemic heart disease in the Caerphilly Heart Study.

AB The relationships of three measurements of the factor VIII/von Willebrand factor (VWF) complex (**factor VIII activity**, FVIIIc (one-stage assay); VWF antigen, VWF Ag (ELISA); and VWF activity, VWF act, measured by a recently-developed ELISA) to major ischaemic heart disease (IHD) events were studied in 1997 men aged 49-65 years, in the second phase of the Caerphilly Heart Study. These variables were related using logistic regression analysis to myocardial infarction or IHD death, which occurred in 129 men during an average follow-up period of 61 months.

All three measurements were highly correlated (r = 0.63-0.77), and each was significantly associated with incident major IHD on univariate analyses (relative odds in highest fifth compared to lowest fifth, 1.68-1.90; P = 0.028-0.006) and on multivariate analyses adjusting for major IHD risk factors and for baseline IHD. Neither FVIIIc nor VWF act was significantly related to incident IHD following adjustment for VWF Ag. We therefore suggest that the associations between these three measurements of the **factor VIII/VWF complex** and incident IHD might have at least three explanations: VWF Ag is a marker of arterial endothelial disturbance; VWF act promotes platelet adhesion/aggregation and hence the platelet component of arterial thrombosis; and FVIIIc promotes fibrin formation and hence the fibrin component of arterial thrombosis.

ACCESSION NUMBER: 1999250512 MEDLINE
DOCUMENT NUMBER: PubMed ID: 10233372
TITLE: Factor VIII, von Willebrand factor and the risk of major ischaemic heart disease in the Caerphilly Heart Study.
AUTHOR: Rumley A; Lowe G D; Sweetnam P M; Yarnell J W; Ford R P
CORPORATE SOURCE: University Department of Medicine, Glasgow Royal Infirmary, Glasgow, UK.
SOURCE: British journal of haematology, (1999 Apr) 105 (1) 110-6. Journal code: 0372544. ISSN: 0007-1048.
PUB. COUNTRY: ENGLAND: United Kingdom
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199906
ENTRY DATE: Entered STN: 19990618
Last Updated on STN: 19990618
Entered Medline: 19990610

L4 ANSWER 2 OF 29 MEDLINE on STN
TI Acquired von Willebrand's syndrome associated with an extranodal pulmonary lymphoma.
AB A case of acquired von Willebrand's syndrome associated with an extranodal pulmonary lymphoma is reported in a 58-year-old man. His initial factor VIII-von Willebrand factor (vWF) complex parameters included a **factor VIII activity** of 29 U/dL, a vWF protein of 17 U/dL, and a ristocetin cofactor of less than 10 U/dL. A specific factor VIII inhibitor could not be demonstrated in mixtures of his plasma and normal pooled plasma nor could immune complexes of IgG-factor VIII be detected in similar mixtures using protein A in a solid phase. Following surgical removal of the patient's tumor, all **factor VIII -vWF complex** parameters returned to normal. Immunoperoxidase stains of the lymphoid tumor cells were negative for von Willebrand protein. The patient's acquired von Willebrand's syndrome recurred approximately one year later, presumably indicative of recurrent lymphoma.

ACCESSION NUMBER: 88105876 MEDLINE
DOCUMENT NUMBER: PubMed ID: 2447850
TITLE: Acquired von Willebrand's syndrome associated with an extranodal pulmonary lymphoma.
AUTHOR: Rao K P; Kizer J; Jones T J; Anunciado A; Pepkowitz S H; Lazarchick J
CORPORATE SOURCE: Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston 29425.
SOURCE: Archives of pathology & laboratory medicine, (1988 Jan) 112 (1) 47-50. Journal code: 7607091. ISSN: 0003-9985.
PUB. COUNTRY: United States
DOCUMENT TYPE: (CASE REPORTS)
Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals

ENTRY MONTH: 198801
ENTRY DATE: Entered STN: 19900305
Last Updated on STN: 19990129
Entered Medline: 19880125

L4 ANSWER 3 OF 29 USPATFULL on STN
TI Delivery of bioactive compounds to an organism
AB Disclosed herein is a method of delivering a bioactive compound to an organism that involves growing individual cells in vitro under conditions that allow the formation of an organized tissue, at least a subset of the cells containing a foreign DNA sequence which mediates the production of the bioactive compound; and implanting the organized tissue into the organism, whereby the bioactive compound is produced and delivered to the organism. Also disclosed herein is an in vitro method for producing a tissue having in vivo-like gross and cellular morphology that involves providing precursor cells of the tissue; mixing the cells with a solution of extracellular matrix components to create a suspension; placing the suspension in a vessel having a three dimensional geometry approximating the in vivo gross and cellular morphology of the tissue and having attachment surfaces coupled thereto; allowing the suspension to coalesce; and culturing the cells under conditions in which the cells form an organized tissue connected to the attachment surfaces. Also disclosed herein is an apparatus for producing in vitro a tissue having in vivo-like gross and cellular morphology. This apparatus includes a vessel having a three dimensional geometry approximating the in vivo morphology of the tissue and tissue attachment surfaces coupled thereto.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:57008 USPATFULL
TITLE: Delivery of bioactive compounds to an organism
INVENTOR(S): Vandenburgh, Herman H., Providence, RI, UNITED STATES
PATENT ASSIGNEE(S): Cell Based Delivery (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004043010	A1	20040304
APPLICATION INFO.:	US 2003-393143	A1	20030320 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1998-118950, filed on 17 Jul 1998, PENDING Continuation-in-part of Ser. No. US 1997-896152, filed on 17 Jul 1997, GRANTED, Pat. No. US 6503504 Continuation-in-part of Ser. No. US 1996-712111, filed on 13 Sep 1996, GRANTED, Pat. No. US 5869041 Continuation-in-part of Ser. No. US 1996-587376, filed on 12 Jan 1996, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	WO 1997-US303	19970110

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: PALMER & DODGE, LLP, KATHLEEN M. WILLIAMS, 111 HUNTINGTON AVENUE, BOSTON, MA, 02199
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 25 Drawing Page(s)
LINE COUNT: 3939
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 4 OF 29 USPATFULL on STN
TI Method of recovering highly purified vWF or **factor VIII/vWF-complex**
AB A method for purifying **factor VIII/vWF complex** or free vWF by immunoaffinity chromatography in a form

suitable for use as a medicament. **Factor VIII/vWF complex** or free vWF is recovered from an immunoaffinity adsorbent by using an eluting agent containing a zwitterionic species. The presence of the zwitterionic species allows for the use of mild conditions throughout the preparation, facilitating retention of molecular integrity, activity, and incorporation of the recovered proteins into pharmaceutical preparations without the need for additional stabilizers or preservatives.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:161896 USPATFULL			
TITLE:	Method of recovering highly purified vWF or **factor VIII/vWF-complex**			
INVENTOR(S):	Mitterer, Artur, Mannsdorf, AUSTRIA Fiedler, Christian, Vienna, AUSTRIA Fischer, Bernhard, Vienna, AUSTRIA Dorner, Friedrich, Vienna, AUSTRIA Eibl, Johann, Vienna, AUSTRIA			
PATENT ASSIGNEE(S):	Baxter Aktiengesellschaft, Vienna, AUSTRIA (non-U.S. corporation)			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6579723	B1	20030617	
	WO 9838218		19980903	
APPLICATION INFO.:	US 1999-367362		19991021	(9)
	WO 1998-AT33		19980218	
	NUMBER		DATE	
PRIORITY INFORMATION:	AT 1997-339		19970227	
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	GRANTED			
PRIMARY EXAMINER:	Le, Long V.			
ASSISTANT EXAMINER:	Gabel, Gailene R.			
LEGAL REPRESENTATIVE:	Townsend and Townsend and Crew LLP			
NUMBER OF CLAIMS:	51			
EXEMPLARY CLAIM:	1			
NUMBER OF DRAWINGS:	1 Drawing Figure(s); 1 Drawing Page(s)			
LINE COUNT:	1046			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 5 OF 29 USPATFULL on STN

TI Method for purifying factor vWF-complex by means of cation exchange chromatography

AB There is disclosed a method of recovering **factor VIII/vWF-complex** which is characterized in that **factor VIII/vWF-complex** from a protein solution is bound to a cation exchanger and is recovered by step-wise elution of **factor VIII/vWF-complex**, which particularly contains high-molecular vWF multimers, as well as a **factor VIII/vWF-complex** obtainable by means of cation exchange chromatography.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2002:112884 USPATFULL
TITLE:	Method for purifying factor vWF-complex by means of cation exchange chromatography
INVENTOR(S):	Mitterer, Artur, Mannsdorf, AUSTRIA Fischer, Bernhard, Vienna, AUSTRIA Schonberger, Oyvind L., Vienna, AUSTRIA Thomas-Urban, Kathrin, Freiburg, GERMANY, FEDERAL REPUBLIC OF

Dorner, Friedrich, Vienna, AUSTRIA
Eibl, Johann, Vienna, AUSTRIA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002058625	A1	20020516
APPLICATION INFO.:	US 2001-3621	A1	20011102 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 2000-367459, filed on 8 May 2000, PENDING A 371 of International Ser. No. WO 1998-AT43, filed on 27 Feb 1998, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	AT 1997-338	19970227

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Page(s)
LINE COUNT: 663
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 6 OF 29 USPATFULL on STN
TI DELIVERY OF BIOACTIVE COMPOUNDS TO AN ORGANISM
AB Disclosed herein is a method of delivering a bioactive compound to an organism that involves growing individual cells in vitro under conditions that allow the formation of an organized tissue, at least a subset of the cells containing a foreign DNA sequence which mediates the production of the bioactive compound; and implanting the organized tissue into the organism, whereby the bioactive compound is produced and delivered to the organism. Also disclosed herein is an in vitro method for producing a tissue having in vivo-like gross and cellular morphology that involves providing precursor cells of the tissue; mixing the cells with a solution of extracellular matrix components to create a suspension; placing the suspension in a vessel having a three dimensional geometry approximating the in vivo gross and cellular morphology of the tissue and having attachment surfaces coupled thereto; allowing the suspension to coalesce; and culturing the cells under conditions in which the cells form an organized tissue connected to the attachment surfaces. Also disclosed herein is an apparatus for producing in vitro a tissue having in vivo-like gross and cellular morphology. This apparatus includes a vessel having a three dimensional geometry approximating the in vivo morphology of the tissue and tissue attachment surfaces coupled thereto.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2002:66628 USPATFULL
TITLE: DELIVERY OF BIOACTIVE COMPOUNDS TO AN ORGANISM
INVENTOR(S): VANDENBURGH, HERMAN H., PROVIDENCE, RI, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002037279	A1	20020328
APPLICATION INFO.:	US 1998-118950	A1	19980717 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1997-896152, filed on 17 Jul 1997, PENDING Continuation-in-part of Ser. No. US 1996-712111, filed on 13 Sep 1996, GRANTED, Pat. No. US 5869041
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: NIXON PEABODY LLP, ATTENTION: DAVID RESNICK, 101 FEDERAL STREET, BOSTON, MA, 02110

NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 25 Drawing Page(s)
LINE COUNT: 3958
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 7 OF 29 USPATFULL on STN
TI Stable **factor VIII / vWF-complex**
AB There are disclosed a stable **factor VIII/vWF -complex**, particularly comprising high-molecular vWF multimers, being free from low-molecular vWF molecules and from proteolytic vWF degradation products, as well as a method of producing this complex.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2002:43190 USPATFULL
TITLE: Stable **factor VIII / vWF-complex**
INVENTOR(S): Fischer, Bernhard, Vienna, AUSTRIA
Mitterer, Artur, Mannsdorf, AUSTRIA
Dorner, Friedrich, Vienna, AUSTRIA
Eibl, Johann, Vienna, AUSTRIA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002025556	A1	20020228
APPLICATION INFO.:	US 2001-849484	A1	20010507 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1998-142768, filed on 6 Nov 1998, GRANTED, Pat. No. US 6228613 A 371 of International Ser. No. WO 1997-AT55, filed on 13 Mar 1997, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	AT 1996-494	19960315

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HELLER EHRMAN WHITE & MCAULIFFE LLP, 1666 K STREET,NW, SUITE 300, WASHINGTON, DC, 20006
NUMBER OF CLAIMS: 43
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 9 Drawing Page(s)
LINE COUNT: 1141
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 8 OF 29 USPATFULL on STN
TI Von willebrand factor derivatives and methods of isolating proteins that bind to von willebrand factor
AB There is disclosed a vWF derivative comprised of vWF, immobilized on a carrier, which is characterized in that the vWF is r-vWF, as well as a method of isolating proteins which bind to vWF, by using this vWF derivative.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2002:32215 USPATFULL
TITLE: Von willebrand factor derivatives and methods of isolating proteins that bind to von willebrand factor
INVENTOR(S): Schwarz, Hans-Peter, Vienna, AUSTRIA
Turecek, Peter, Klosterneuburg, AUSTRIA
Eibl, Johann, Vienna, AUSTRIA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002019036	A1	20020214

APPLICATION INFO.: US 2001-967937 A1 20011002 (9)
RELATED APPLN. INFO.: Division of Ser. No. US 1999-319116, filed on 2 Jun 1999, PENDING A 371 of International Ser. No. WO 1997-AT253, filed on 19 Nov 1997, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	AT 1996-2178	19961213

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HELLER EHRMAN WHITE & MCAULIFFE LLP, 1666 K STREET,NW, SUITE 300, WASHINGTON, DC, 20006
NUMBER OF CLAIMS: 22
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Page(s)
LINE COUNT: 598
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 9 OF 29 USPATFULL on STN
TI Highly purified factor VIII complex
AB There is disclosed a highly purified complex comprising the components factor VIII and vWF having a specific activity of at least 70, preferably 100 to 300 U factor VIII:C/mg, a stable pharmaceutical preparation containing this complex as well as a method of producing the same.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2001:185463 USPATFULL
TITLE: Highly purified factor VIII complex
INVENTOR(S): Schonhofer, Wolfgang, Polten, Austria
Eibl, Johann, Vienna, Austria
Weber, Alfred, Vienna, Austria
Linnau, Yendra, Vienna, Austria
PATENT ASSIGNEE(S): Baxter Aktiengesellschaft, Vienna, Austria (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6307032	B1	20011023	
	WO 9739033		19971023	
APPLICATION INFO.:	US 1998-171121		19981118	(9)
	WO 1997-AT69		19970409	
			19981118	PCT 371 date
			19981118	PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	AT 1996-667	19960412

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Carlson, Karen Cochrane
ASSISTANT EXAMINER: Schnizer, Holly
LEGAL REPRESENTATIVE: Heller Ehrman White & McAuliffe
NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
LINE COUNT: 509
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 10 OF 29 USPATFULL on STN
TI Stable factor VIII/von Willebrand factor complex
AB There are disclosed a stable **factor VIII/vWF -complex**, particularly comprising high-molecular vWF multimers, being free from low-molecular vWF molecules and from proteolytic vWF degradation products, as well as a method of producing

this complex.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2001:67424 USPATFULL			
TITLE:	Stable factor VIII/von Willebrand factor complex			
INVENTOR(S):	Fischer, Bernhard, Vienna, Austria Mitterer, Artur, Mannsdorf, Austria Dorner, Friedrich, Vienna, Austria Eibl, Johann, Vienna, Austria			
PATENT ASSIGNEE(S):	Baxter Aktiengesellschaft, Vienna, Austria (non-U.S. corporation)			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6228613	B1	20010508	
	WO 9734930		19970925	
APPLICATION INFO.:	US 1998-142768		19981106	(9)
	WO 1997-AT55		19970313	
			19981106	PCT 371 date
			19981106	PCT 102(e) date
	NUMBER		DATE	
PRIORITY INFORMATION:	AT 1996-494		19960315	
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	Granted			
PRIMARY EXAMINER:	Carlson, Karen Cochrane			
ASSISTANT EXAMINER:	Robinson, Hope A.			
LEGAL REPRESENTATIVE:	Heller Ehrman White & McAuliffe			
NUMBER OF CLAIMS:	40			
EXEMPLARY CLAIM:	1			
NUMBER OF DRAWINGS:	9 Drawing Figure(s); 9 Drawing Page(s)			
LINE COUNT:	1098			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 11 OF 29 USPATFULL on STN

TI Vectors and cell lines capable of correctly splicing exon regions

AB A recombinant DNA vector is provided that expresses exons of genomic DNA fragments that are inserted into the vector. The vector contains a promoter and a genomic DNA fragment so characterized and configured that the vector, upon transcription in a transfected eukaryotic cell culture, expresses the corresponding RNA segment of the genomic DNA fragment free of any intron.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	97:101662 USPATFULL			
TITLE:	Vectors and cell lines capable of correctly splicing exon regions			
INVENTOR(S):	Capon, Daniel J., San Mateo, CA, United States Lawn, Richard M., San Francisco, CA, United States Vehar, Gordon A., San Carlos, CA, United States Wood, William I., San Mateo, CA, United States			
PATENT ASSIGNEE(S):	Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5683905		19971104	
APPLICATION INFO.:	US 1995-448171		19950523	(8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1990-595481, filed on 9 Oct 1990 which is a continuation of Ser. No. US 1987-83758, filed on 7 Aug 1987, now patented, Pat. No. US 4965199 which is a continuation of Ser. No. US 1984-602312, filed on 20 Apr 1984, now abandoned			

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Robinson, Douglas W.
ASSISTANT EXAMINER: Wai, Thanda
LEGAL REPRESENTATIVE: Hasak, Janet E., McNicholas, Janet M.
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 41 Drawing Figure(s); 32 Drawing Page(s)
LINE COUNT: 2579
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 12 OF 29 USPATFULL on STN
TI Preparation of functional human factor VIII and pharmaceutical treatment therewith
AB Functional human factor VIII produced recombinantly is used in the treatment of human beings diagnosed to be deficient in factor VIII coagulant activity. Also provided are DNA isolates and expression vehicles encoding functional human factor VIII, as well as transformed host cells and processes for producing human factor VIII by use of recombinant DNA technology.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 97:83935 USPATFULL
TITLE: Preparation of functional human factor VIII and pharmaceutical treatment therewith
INVENTOR(S): Capon, Daniel J., San Mateo, CA, United States
Lawn, Richard M., San Francisco, CA, United States
Vehar, Gordon A., San Carlos, CA, United States
Wood, William I., San Mateo, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5668108		19970916
APPLICATION INFO.:	US 1995-447654		19950523 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1990-570096, filed on 20 Aug 1990, now patented, Pat. No. US 5618788 which is a continuation of Ser. No. US 1987-83758, filed on 7 Aug 1987, now patented, Pat. No. US 4965199 which is a continuation of Ser. No. US 1984-602312, filed on 20 Apr 1984, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Jacobson, Dian C.
LEGAL REPRESENTATIVE: Hasak, Janet E.
NUMBER OF CLAIMS: 2
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 41 Drawing Figure(s); 32 Drawing Page(s)
LINE COUNT: 2566
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 13 OF 29 USPATFULL on STN
TI Method of hybridization using oligonucleotide probes
AB An improved method of hybridization with oligonucleotide probes using tetramethylammonium chloride is provided. The method is useful for screening mixtures of DNA sequences, including libraries of high DNA sequence complexity, with a single oligonucleotide probe or a pool of probes representing all possible codon choices for a short amino acid sequence.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 97:68321 USPATFULL
TITLE: Method of hybridization using oligonucleotide probes

INVENTOR(S): Wood, William I., San Mateo, CA, United States
Lasky, Laurence A., Sausalito, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5654147		19970805
APPLICATION INFO.:	US 1995-447486		19950523 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1992-829867, filed on 3 Feb 1992, now patented, Pat. No. US 5618789 which is a division of Ser. No. US 1990-570096, filed on 20 Aug 1990, now patented, Pat. No. US 5618788 which is a continuation of Ser. No. US 1987-83758, filed on 7 Aug 1987, now patented, Pat. No. US 4965199 which is a continuation of Ser. No. US 1984-602312, filed on 20 Apr 1984, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Jones, W. Gary
ASSISTANT EXAMINER: Rees, Dianne
LEGAL REPRESENTATIVE: Hasak, Janet E.
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 41 Drawing Figure(s); 32 Drawing Page(s)
LINE COUNT: 2586
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 14 OF 29 USPATFULL on STN
TI Preparation of functional human factor VIII
AB Functional human factor VIII produced recombinantly is used in the treatment of human beings diagnosed to be deficient in factor VIII coagulant activity. Also provided are DNA isolates and expression vehicles encoding functional human factor VIII, as well as transformed host cells and processes for producing human factor VIII by use of recombinant DNA technology.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 97:44916 USPATFULL
TITLE: Preparation of functional human factor VIII
INVENTOR(S): Wood, William I., San Mateo, CA, United States
Capon, Daniel J., San Mateo, CA, United States
Lawn, Richard M., San Francisco, CA, United States
Vehar, Gordon A., San Carlos, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5633150		19970527
APPLICATION INFO.:	US 1990-595481		19901009 (7)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1987-83758, filed on 7 Aug 1987, now patented, Pat. No. US 4965199 which is a continuation of Ser. No. US 1984-602312, filed on 20 Apr 1984, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Jacobson, Dian C.
LEGAL REPRESENTATIVE: Hasak, Janet E.
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 40 Drawing Figure(s); 32 Drawing Page(s)
LINE COUNT: 2495
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 15 OF 29 USPATFULL on STN
TI Functional human factor VIII
AB Functional human factor VIII produced recombinantly is used in the treatment of human beings diagnosed to be deficient in factor VIII coagulant activity. Also provided are DNA isolates and expression vehicles encoding functional human factor VIII, as well as transformed host cells and processes for producing human factor VIII by use of recombinant DNA technology.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	97:29446 USPATFULL
TITLE:	Functional human factor VIII
INVENTOR(S):	Capon, Daniel J., San Mateo, CA, United States Lawn, Richard M., San Francisco, CA, United States Vehar, Gordon A., San Carlos, CA, United States Wood, William I., San Mateo, CA, United States
PATENT ASSIGNEE(S):	Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5618789		19970408	
APPLICATION INFO.:	US 1992-829867		19920203	(7)
RELATED APPLN. INFO.:	Division of Ser. No. US 1990-570096, filed on 20 Aug 1990 which is a continuation of Ser. No. US 1987-83758, filed on 7 Aug 1987, now patented, Pat. No. US 4965199 which is a continuation of Ser. No. US 1984-602312, filed on 20 Apr 1984, now abandoned			

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Jacobson, Dian C.
LEGAL REPRESENTATIVE:	Hasak, Janet E.
NUMBER OF CLAIMS:	7
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	41 Drawing Figure(s); 32 Drawing Page(s)
LINE COUNT:	2485

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 16 OF 29 USPATFULL on STN
TI Preparation of functional human factor VIII and pharmaceutical treatment therewith
AB Functional human factor VIII produced recombinantly is used in the treatment of human beings diagnosed to be deficient in factor VIII coagulant activity. Also provided are DNA isolates and expression vehicles encoding functional human factor VIII, as well as transformed host cells and processes for producing human factor VIII by use of recombinant DNA technology.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	97:29445 USPATFULL
TITLE:	Preparation of functional human factor VIII and pharmaceutical treatment therewith
INVENTOR(S):	Capon, Daniel J., San Mateo, CA, United States Lawn, Richard M., San Francisco, CA, United States Vehar, Gordon A., San Carlos, CA, United States Wood, William I., San Mateo, CA, United States
PATENT ASSIGNEE(S):	Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5618788		19970408	
APPLICATION INFO.:	US 1990-570096		19900820	(7)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1987-83758, filed on 7 Aug 1987, now patented, Pat. No. US 4965199 which is a continuation of Ser. No. US 1984-602312, filed on 20 Apr 1984, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Jacobson, Dian C.
LEGAL REPRESENTATIVE: Hasak, Janet E.
NUMBER OF CLAIMS: 1
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 41 Drawing Figure(s); 32 Drawing Page(s)
LINE COUNT: 2536
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 17 OF 29 USPATFULL on STN
TI Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
AB A method for producing factor VIII in recombinant mammalian host cells utilizing an expression vector containing a selectable marker DNA and an amplifiable marker DNA. The initial selection is based upon the selectable marker and subsequent amplification of factor VIII DNA and amplifiable marker DNA is conducted in cells not deficient in the amplifiable marker.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 90:81726 USPATFULL
TITLE: Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
INVENTOR(S): Capon, Daniel J., San Mateo, CA, United States
Lawn, Richard M., San Francisco, CA, United States
Levinson, Arthur D., Hillsborough, CA, United States
Vehar, Gordon A., San Carlos, CA, United States
Wood, William I., San Mateo, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4965199		19901023
APPLICATION INFO.:	US 1987-83758		19870807 (7)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1984-602312, filed on 20 Apr 1984
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Teskin, Robin L.
LEGAL REPRESENTATIVE: Hasak, Janet E.
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 32 Drawing Figure(s); 32 Drawing Page(s)
LINE COUNT: 2416
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 18 OF 29 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
TI Regulation of **factor VIII activity** by the factor VIIa-tissue factor complex.
AB Blood coagulation is triggered at the site of vascular damage when exposed tissue factor (TF) contacts plasma factor VIIa (fVIIa). The resulting enzyme-cofactor complex (fVIIa-TF) activates fX and fIX by limited proteolysis to generate fXa and fIXa and propagate/amplify the coagulant response. Although this is the accepted mechanism for coagulation initiation under normal conditions and has been the focus of many studies, other relatively "minor" (and thus understudied) pathways may manifest themselves and be of greater importance under various pathological

conditions in which TF has been implicated. Our previous studies have demonstrated that the fVIIa-TF complex can cleave fVIII, the essential procofactor for fIXa. While these experiments were done using recombinant fVIII in vitro and showed the product as being largely inactivated fVIII, an initial transient twofold increase in fVIIIa clotting activity was observed. This may be of import in vivo when considering the potential for TF-containing microparticles to fuse with fVIII-rich platelet microparticles as well as the recent description of alternatively-spliced TF that can localize to platelets. This possibility prompted us to examine the ability of the fVIIa-TF complex to regulate fVIII activity in plasma. Activation of fVIII was measured using fX-deficient plasma as the fVIII source in the presence or absence of fVIIa in complex with TFK165,166A (a mutant form of TF that does not support cleavage of fIX or fX). An immediate TF-dependent increase in activity of fVIIIa was observed which peaked at 5 minutes (7-10 fold maximum increase in fVIIIa activity). This elevated fVIIIa activity persisted for greater than 60 min and its appearance was not affected by inclusion of soybean trypsin inhibitor (1 muM) or hirudin (1 U/ml), ruling out fVIII activation by the two known phsyiological fVIII activators factor Xa and thrombin. In addition, no measurable thrombin was detectable in assays of fVIIa-TF activation of fVIII over 60 min, and no clot was observed over this time period. As a comparison, addition of low levels of thrombin to the plasma resulted in much different kinetics with rapid appearance and decay of fVIIIa activity and formation of a clot. Assays done using the purified fVIII-vWf complex (Koate) in vitro showed similar activation kinetics by fVIIa-TF to that observed in plasma. From this data we propose that the fVIIa-TF complex can activate fVIII in plasma and that the fVIIIa activity produced is longer-lived than that obtained by fVIII activation with thrombin. Thus, activation of fVIII by the fVIIa-TF complex in this way would allow sustained low-level coagulation for much longer durations than fVIII activation by thrombin or fXa. While likely not of consequence in hemostasis, this would be expected to be of great consequence in disease states or wound-healing scenarios where such long-term interactions between these proteins can occur, thus potentially affecting a long-term prothrombotic state.

ACCESSION NUMBER: 2004:153816 BIOSIS
DOCUMENT NUMBER: PREV200400148262
TITLE: Regulation of **factor VIII activity** by the factor VIIa-tissue factor complex.
AUTHOR(S): Neuenschwander, Pierre F. [Reprint Author]
CORPORATE SOURCE: Biochemistry, University of Texas Health Center at Tyler, Tyler, TX, USA
SOURCE: Blood, (November 16 2003) Vol. 102, No. 11, pp. 749a. print.
Meeting Info.: 45th Annual Meeting of the American Society of Hematology. San Diego, CA, USA. December 06-09, 2003. American Society of Hematology.
CODEN: BLOOAW. ISSN: 0006-4971.
DOCUMENT TYPE: Conference; (Meeting)
Conference; (Meeting Poster)
Conference; Abstract; (Meeting Abstract)
LANGUAGE: English
ENTRY DATE: Entered STN: 17 Mar 2004
Last Updated on STN: 17 Mar 2004

L4 ANSWER 19 OF 29 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
TI Factor VIII, von Willebrand factor and the risk of major ischaemic heart disease in the Caerphilly Heart Study.
AB The relationships of three measurements of the factor VIII/von Willebrand factor (VWF) complex (**factor VIII activity**.
FVIIIc (one-stage assay); VWF antigen, VWF Ag (ELISA); and VWF activity, VWF act, measured by a recently-developed ELISA) to major ischaemic heart disease (IHD) events were studied in 1997 men aged 49-65 years, in the

second phase of the Caerphilly Heart Study. These variables were related using logistic regression analysis to myocardial infarction or IHD death, which occurred in 129 men during an average follow-up period of 61 months. All three measurements were highly correlated (r=0.63-0.77), and each was significantly associated with incident major IHD on univariate analyses (relative odds in highest fifth compared to lowest fifth, 1.68-1.90; P=0.028-0.006) and on multivariate analyses adjusting for major IHD risk factors and for baseline IHD. Neither FVIIIc nor VWF act was significantly related to incident IHD following adjustment for VWF Ag. We therefore suggest that the associations between these three measurements of the **factor VIII/VWF complex** and incident IHD might have at least three explanations: VWF Ag is a marker of arterial endothelial disturbance; VWF act promotes platelet adhesion/aggregation and hence the platelet component of arterial thrombosis; and FVIIIc promotes fibrin formation and hence the fibrin component of arterial thrombosis.

ACCESSION NUMBER: 1999:261609 BIOSIS
DOCUMENT NUMBER: PREV199900261609
TITLE: Factor VIII, von Willebrand factor and the risk of major ischaemic heart disease in the Caerphilly Heart Study.
AUTHOR(S): Rumley, A.; Lowe, G. D. O. [Reprint author]; Sweetnam, P. M.; Yarnell, J. W. G.; Ford, R. P.
CORPORATE SOURCE: University Department of Medicine, Glasgow Royal Infirmary, 10 Alexandra Parade, Glasgow, G31 2ER, UK
SOURCE: British Journal of Haematology, (April, 1999) Vol. 105, No. 1, pp. 110-116. print.
CODEN: BJHEAL. ISSN: 0007-1048.
DOCUMENT TYPE: Article
LANGUAGE: English
ENTRY DATE: Entered STN: 2 Jul 1999
Last Updated on STN: 2 Jul 1999

L4 ANSWER 20 OF 29 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
TI THE RELATIONSHIP BETWEEN COAGULATION FACTOR VIII AND ABO BLOOD GROUP STATUS.
AB Procoagulant **factor VIII activity** (VIII:C) and procoagulant antigen (VIII:Ag) levels were measured in 402 blood donors (blood group O = 182, A = 160, B = 49 and AB = 11) to determine whether the measured activity (VIII:C) of the VIII component of the factor VIII/von Willebrand **factor (VIII/vWF) complex** was reflected in the level of the antigen (VIII:Ag). Both VIII:C and VIII:Ag were significantly and similarly lower in blood group O individuals than in those of other blood groups. However, there was no significant difference between VIII:C activity and VIII:Ag levels for each of the ABO blood groups (i.e. VIII:C/VIII:Ag ratios = 1.0).

ACCESSION NUMBER: 1988:287290 BIOSIS
DOCUMENT NUMBER: PREV198886015557; BA86:15557
TITLE: THE RELATIONSHIP BETWEEN COAGULATION FACTOR VIII AND ABO BLOOD GROUP STATUS.
AUTHOR(S): MCLELLAN D S [Reprint author]; KNIGHT S R; ARONSTAM A
CORPORATE SOURCE: SCH PHARMACY AND BIOMEDICAL SCI, PORTSMOUTH POLYTECHNIC, PORTSMOUTH, HAMPSHIRE, UK
SOURCE: Medical Laboratory Sciences, (1988) Vol. 45, No. 2, pp. 131-134.
CODEN: MLASDU. ISSN: 0308-3616.
DOCUMENT TYPE: Article
FILE SEGMENT: BA
LANGUAGE: ENGLISH
ENTRY DATE: Entered STN: 16 Jun 1988
Last Updated on STN: 16 Jun 1988

L4 ANSWER 21 OF 29 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN

TI ACQUIRED VON WILLEBRAND'S SYNDROME ASSOCIATED WITH AN EXTRANODAL PULMONARY LYMPHOMA.

AB A case of acquired von Willebrand's syndrome associated with an extranodal pulmonary lymphoma is reported in a 58-year-old man. His initial factor VIII-von Willebrand factor (vWF) complex parameters included a **factor VIII activity** of 29 U/dL, a vWF protein of 17 U/dL, and a ristocetin cofactor of < 10 U/dL. A specific factor VIII inhibitor could not be demonstrated in mixtures of his plasma and normal pooled plasma nor could immune complexes of IgG-factor VIII be detected in similar mixtures using protein A in a solid phase. Following surgical removal of the patient's tumor, all **factor VIII -vWF complex** parameters returned to normal. Immunoperoxidase stains of the lymphoid tumor cells were negative for von Willebrand protein. The patient's acquired von Willebrand's syndrome recurred approximately one year later, presumably indicative of recurrent lymphoma.

ACCESSION NUMBER: 1988:135066 BIOSIS
DOCUMENT NUMBER: PREV198885069893; BA85:69893
TITLE: ACQUIRED VON WILLEBRAND'S SYNDROME ASSOCIATED WITH AN EXTRANODAL PULMONARY LYMPHOMA.
AUTHOR(S): RAO K P P [Reprint author]; KIZER J; JONES T J; ANUNCIADO A; PEPKOWITZ S H; LAZARCHICK J
CORPORATE SOURCE: DEP PATHOL LAB MED, MED UNIV SOUTH CAROLINA, 171 ASHLEY AVE, CHARLESTON, SC 29425, USA
SOURCE: Archives of Pathology and Laboratory Medicine, (1988) Vol. 112, No. 1, pp. 47-50.
CODEN: ARPAAQ. ISSN: 0363-0153.
DOCUMENT TYPE: Article
FILE SEGMENT: BA
LANGUAGE: ENGLISH
ENTRY DATE: Entered STN: 12 Mar 1988
Last Updated on STN: 12 Mar 1988

L4 ANSWER 22 OF 29 WPIDS COPYRIGHT 2004 THE THOMSON CORP on STN

TI Carrier-fixed recombinant von Willebrand factor derivative - useful for isolating proteins binding von Willebrand factor, e.g. factor VIII, in high yield.

AN 1998-348459 [30] WPIDS

AB WO 9825969 A UPAB: 19980730

Derivative (I) of von Willebrand Factor (vWF) consists of recombinant vWF (r-vWF) immobilised on a particulate or gel carrier (II).

Also claimed are:

(1) a method for isolating vWF-binding proteins (III), comprising:

(a) contacting a fraction containing (III) with (I) so that (III) bind with (I);

(b) removing the non-bound components, and

(c) eluting (III) from (I), and

(2) a device consisting of a container (specifically an affinity column) containing (I) and having an inlet and an outlet for liquid.

USE - The method and device are useful for removing, recovering, purifying and/or concentrating (III) contained in liquid samples, specifically fractions contained in a mammalian body fluid or cell culture sample.

(III) is e.g. glycoprotein Ib, the glycoprotein in IIb/IIIa complex, collagen, factor VIII (including recombinant derivatives and analogues), vWF antigen, vWF antibody or an enzyme recognising vWF as substrate (e.g. vWF multimerase or vWF depolymerase).

Saccharides binding vWF (e.g. heparin) can also be isolated.

Typical applications are: isolation of pure proteins with **factor VIII activity** for biochemical-analytical, diagnostic or therapeutic use; purification of vWF multimerase; extra-corporeal immuno-adsorption of anti-vWF antibodies (associated with pathological states such as auto-immune disease); or preparative recovery of mono- or poly-clonal anti-vWF antibodies for

diagnostic use.

ADVANTAGE - The affinity of (I) for (III) is higher than that of plasma vWF, so that (III) can be isolated even from solutions containing vWF (e.g. in **factor VIII-vWF complex**).

(III) can be isolated in high yield, specifically at least 80% (claimed). (I) have high stability, can be used repeatedly and retain the 'nativity' of vWF. r-vWF is readily available in high purity.

Dwg.0/2

ACCESSION NUMBER: 1998-348459 [30] WPIDS
DOC. NO. CPI: C1998-107760
TITLE: Carrier-fixed recombinant von Willebrand factor derivative - useful for isolating proteins binding von Willebrand factor, e.g. factor VIII, in high yield.
DERWENT CLASS: B04 D16
INVENTOR(S): EIBL, J; SCHWARZ, H; TURECEK, P
PATENT ASSIGNEE(S): (IMMO) IMMUNO AG; (BAXT) BAXTER AG; (EIBL-I) EIBL J; (SCHW-I) SCHWARZ H; (TURE-I) TURECEK P
COUNTRY COUNT: 22
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 9825969	A1	19980618	(199830)*	GE	29
RW: AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE					
W: CZ HU JP US					
AT 9602178	A	19990315	(199916)		
AT 405740	B	19990915	(199942)		
CZ 9902112	A3	19990915	(199945)		
EP 954533	A1	19991110	(199952)	GE	
R: AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE					
HU 9903789	A2	20000328	(200025)		
JP 2001506987	W	20010529	(200136)		22
US 2002019036	A1	20020214	(200214)		

APPLICATION DETAILS:

PATENT NO	KIND		APPLICATION	DATE
WO 9825969	A1		WO 1997-AT253	19971119
AT 9602178	A		AT 1996-2178	19961213
AT 405740	B		AT 1996-2178	19961213
CZ 9902112	A3		WO 1997-AT253	19971119
			CZ 1999-2112	19971119
EP 954533	A1		EP 1997-913009	19971119
			WO 1997-AT253	19971119
HU 9903789	A2		WO 1997-AT253	19971119
			HU 1999-3789	19971119
JP 2001506987	W		WO 1997-AT253	19971119
			JP 1998-526003	19971119
US 2002019036	A1	Div ex	WO 1997-AT253	19971119
		Div ex	US 1999-319116	19990602
			US 2001-967937	20011002

FILING DETAILS:

PATENT NO	KIND		PATENT NO
AT 405740	B	Previous Publ.	AT 9602178
CZ 9902112	A3	Based on	WO 9825969
EP 954533	A1	Based on	WO 9825969
HU 9903789	A2	Based on	WO 9825969
JP 2001506987	W	Based on	WO 9825969

PRIORITY APPLN. INFO: AT 1996-2178 19961213

L4 ANSWER 23 OF 29 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN

TI Factor VIII, von Willebrand factor and the risk of major ischaemic heart disease in the Caerphilly Heart Study.

AB The relationships of three measurements of the factor VIII/von Willebrand factor (VWF) complex (**factor VIII activity**, FVIIIc (one-stage assay); VWF antigen, VWF Ag (ELISA); and VWF activity, VWF act, measured by a recently-developed ELISA) to major ischaemic heart disease (IHD) events were studied in 1997 men aged 49-65 years, in the second phase of the Caerphilly Heart Study. These variables were related using logistic regression analysis to myocardial infarction or IHD death, which occurred in 129 men during an average follow-up period of 61 months. All three measurements were highly correlated (r = 0.63-0.77), and each was significantly associated with incident major IHD on univariate analyses (relative odds in highest fifth compared to lowest fifth, 1.68-1.90; P=0.028-0.006) and on multivariate analyses adjusting for major IHD risk factors and for baseline IHD. Neither FVIIIc nor VWF act was significantly related to incident IHD following adjustment for VWF Ag. We therefore suggest that the associations between these three measurements of the **factor VIII/VWF complex** and incident IHD might have at least three explanations: VWF Ag is a marker of arterial endothelial disturbance; VWF act promotes platelet adhesion/aggregation and hence the platelet component of arterial thrombosis; and FVIIIc promotes fibrin formation and hence the fibrin component of arterial thrombosis.

ACCESSION NUMBER: 1999150325 EMBASE
TITLE: Factor VIII, von Willebrand factor and the risk of major ischaemic heart disease in the Caerphilly Heart Study.
AUTHOR: Rumley A.; Lowe G.D.O.; Sweetnam P.M.; Yarnell J.W.G.; Ford R.P.
CORPORATE SOURCE: Prof. G.D.O. Lowe, University Department of Medicine, Glasgow Royal Infirmary, 10 Alexandra Parade, Glasgow G31 2ER, United Kingdom
SOURCE: British Journal of Haematology, (1999) 105/1 (110-116). Refs: 24
ISSN: 0007-1048 CODEN: BJHEAL
COUNTRY: United Kingdom
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 017 Public Health, Social Medicine and Epidemiology
018 Cardiovascular Diseases and Cardiovascular Surgery
025 Hematology
LANGUAGE: English
SUMMARY LANGUAGE: English

L4 ANSWER 24 OF 29 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN

TI The relationship between coagulation factor VIII and ABO blood group status.

AB Procoagulant **factor VIII activity** (VIII:C) and procoagulant antigen (VIII:Ag) levels were measured in 402 blood donors (blood group O = 182, A = 160, B = 49 and AB = 11) to determine whether the measured activity (VIII:C) of the VIII component of the factor VIII/von Willebrand **factor** (**VIII/vWF**) **complex** was reflected in the level of the antigen (VIII:Ag). Both VIII:C and VIII:Ag were significantly and similarly lower in blood group O individuals than in those of other blood groups. However, there was no significant difference between VIII:C activity and VIII:Ag levels for each of the ABO blood groups (i.e. VIII:C/VIII:Ag ratios = 1.0).

ACCESSION NUMBER: 88124888 EMBASE
DOCUMENT NUMBER: 1988124888
TITLE: The relationship between coagulation factor VIII and ABO blood group status.

AUTHOR: McLellan D.S.; Knight S.R.; Aronstam A.
CORPORATE SOURCE: School of Pharmacy and Biomedical Sciences, Portsmouth Polytechnic, Portsmouth, Hampshire, United Kingdom
SOURCE: Medical Laboratory Sciences, (1988) 45/2 (131-134).
ISSN: 0308-3616 CODEN: MLASDU
COUNTRY: United Kingdom
DOCUMENT TYPE: Journal
FILE SEGMENT: 025 Hematology
LANGUAGE: English
SUMMARY LANGUAGE: English

L4 ANSWER 25 OF 29 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
TI Acquired von Willebrand's syndrome associated with an extranodal pulmonary lymphoma.
AB A case of acquired von Willebrand's syndrome associated with an extranodal pulmonary lymphoma is reported in a 58-year-old man. His initial factor VIII-von Willebrand factor (vWF) complex parameters included a **factor VIII activity** of 29 U/dL, a vWF protein of 17 U/dL, and a ristocetin cofactor of <10 U/dL. A specific factor VIII inhibitor could not be demonstrated in mixtures of his plasma and normal pooled plasma nor could immune complexes of IgG-factor VIII be detected in similar mixtures using protein A in a solid phase. Following surgical removal of the patient's tumor, all **factor VIII-vWF complex** parameters returned to normal. Immunoperoxidase stains of the lymphoid tumor cells were negative for von Willebrand protein. The patient's acquired Von Willebrand's syndrome recurred approximately one year later, presumably indicative of recurrent lymphoma.
ACCESSION NUMBER: 88025592 EMBASE
DOCUMENT NUMBER: 1988025592
TITLE: Acquired von Willebrand's syndrome associated with an extranodal pulmonary lymphoma.
AUTHOR: Rao K.P.P.; Kizer J.; Jones T.J.; Anunciado A.; Pepkowitz S.H.; Lazarchick J.
CORPORATE SOURCE: Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, SC 29425, United States
SOURCE: Archives of Pathology and Laboratory Medicine, (1988) 112/1 (47-50).
ISSN: 0003-9985 CODEN: ARPAAQ
COUNTRY: United States
DOCUMENT TYPE: Journal
FILE SEGMENT: 005 General Pathology and Pathological Anatomy
015 Chest Diseases, Thoracic Surgery and Tuberculosis
016 Cancer
025 Hematology
LANGUAGE: English
SUMMARY LANGUAGE: English

L4 ANSWER 26 OF 29 HCAPLUS COPYRIGHT 2004 ACS on STN
TI Analysis of free factor VIII antigen in commercial factor VIII concentrates
AB The association of factor VIII with von Willebrand factor (vWF) is important for protection of factor VIII against proteolytic degradation in plasma. Recently developed factor VIII prepns., namely monoclonal antibody-purified factor VIII (M-factor VIII) and recombinant factor VIII, contain free form of factor VIII that is expected to form complexes with endogenous vWF after venous injection in the patients with hemophilia A. To clarify the difference of free factor VIII and **factor VIII-vWF complex** in the com. factor VIII concs., we developed a quant. assay for free factor VIII in which the sample was added to the wells of vWF-coated microtiter plates. Bound factor VIII was detected by monoclonal antibody against factor VIII,

followed by incubation with peroxidase conjugated anti-mouse IgG, then the substrate ABTS for measuring absorbance at 405 nm. When the amount of free factor VIII antigen in one unit **factor VIII activity** of recombinant factor VIII was defined as one arbitrary unit, the ELISA detected free factor VIII as low as 0.016 unit/mL. Factor VIII was incubated with vWF or plasma from a patient with severe Hemophilia A for various concns., prior to the free factor VIII assay. At saturation, the stoichiometry was one factor VIII mol. per 50 vWF monomers. Of the products of **factor VIII-vWF complex** concentrate, no free factor VIII was detected. While a M-factor VIII concentrate contained free factor VIII comprising 24% of total **factor VIII activity**. In a gel filtration experiment of M-factor VIII, 15% of the total factor VIII was eluted as free factor VIII and 77% of that was co-eluted with vWF in the void volume The free factor VIII and the complex form of factor VIII were immunoisolated and were analyzed after SDS-PAGE by immunoblotting. The factor VIII mol. structure and the susceptibility of thrombin cleavage were indistinguishable between the two forms of factor VIII. These results suggested that free factor VIII present in the M-factor VIII concentrate forms complexes with vWF in hemophilic plasma and is involved in physiol. hemostasis.

ACCESSION NUMBER: 1997:262983 HCAPLUS
DOCUMENT NUMBER: 126:321126
TITLE: Analysis of free factor VIII antigen in commercial factor VIII concentrates
AUTHOR(S): Watanabe, Jun; Arai, Morio; Kagawa, Kazuhiko; Amano, Kagehiro; Fukutake, Katsuyuki
CORPORATE SOURCE: Dept. Clinical Pathology, Tokyo Medical College, Tokyo, 160, Japan
SOURCE: Nippon Kessen Shiketsu Gakkaishi (1997), 8(1), 44-54
CODEN: NKSGEL; ISSN: 0915-7441
PUBLISHER: Nippon Kessen Shiketsu Gakkai
DOCUMENT TYPE: Journal
LANGUAGE: Japanese

L4 ANSWER 27 OF 29 JICST-EPlus COPYRIGHT 2004 JST on STN
TI Detection and Characterization of an Anti-Factor VIII Antibody that Does Not Inhibit Biological Activity.
AB One of the major factors complicating the treatment of hemophilia A is development of factor VIII inhibitors, which represent anti-factor VIII alloantibodies. Hitherto, inhibitors have been recognized to be acquired antibodies that neutralize **factor VIII activity**, and they have been routinely measured with the Bethesda assay based on their inhibitory action on **factor VIII activity**. In the present study, the authors used immunochemical methods to investigate the properties of an anti-factor VIII antibody recovered from a patient in whom inhibitor was not detectable with the Bethesda method (.LEQ.0.4), but in whom in vivo recovery rate of factor VIII preparations was abnormally decreased to below 50%. Using a purified factor VIII preparation as an antigen, SDS-polyacrylamide-gel electrophoresis (SDS-PAGE) and Western blotting were performed, with the preparation reacted with patient plasma. As a result, the antibody was detected as an IgG antibody bound to an 80kDa factor VIII light chain band. Then, the influence exerted by this antibody on the binding of factor VIII and von Willebrand factor (vWF), which forms a non-covalent bond with factor VIII, thereby stabilizing the latter as a carrier protein and which is thought to also enhance thrombin-mediated **factor VIII activity**, was investigated. In an ELISA using anti-factor VIII monoclonal antibody as the capture antibody and anti-vWF antibody as the tag antibody, IgG (2.2mg/ml) prepared from patient plasma and a recombinant factor VIII preparation (r-F VIII) were reacted and then mixed with vWF. However, no inhibition of **factor VIII/vWF complex** formation was found. (abridged author abst.)
ACCESSION NUMBER: 920822061 JICST-EPlus

TITLE: Detection and Characterization of an Anti-Factor VIII Antibody that Does Not Inhibit Biological Activity.
AUTHOR: KOSHIHARA KIMIHITO; FUKUTAKE KATSUYUKI; ARAI MORIO
CORPORATE SOURCE: Tokyo Medical College
SOURCE: Tokyo Ika Daigaku Zasshi (Journal of Tokyo Medical College), (1992) vol. 50, no. 5, pp. 801-807. Journal Code: F0570A (Fig. 2, Tbl. 3, Ref. 20)
CODEN: TIDZAH; ISSN: 0040-8905
PUB. COUNTRY: Japan
DOCUMENT TYPE: Journal; Article
LANGUAGE: Japanese
STATUS: New

L4 ANSWER 28 OF 29 WPIX COPYRIGHT 2004 THE THOMSON CORP on STN
TI Carrier-fixed recombinant von Willebrand factor derivative - useful for isolating proteins binding von Willebrand factor, e.g. factor VIII, in high yield.
AN 1998-348459 [30] WPIX
AB WO 9825969 A UPAB: 19980730
Derivative (I) of von Willebrand Factor (vWF) consists of recombinant vWF (r-vWF) immobilised on a particulate or gel carrier (II).
Also claimed are:
(1) a method for isolating vWF-binding proteins (III), comprising:
(a) contacting a fraction containing (III) with (I) so that (III) bind with (I);
(b) removing the non-bound components, and
(c) eluting (III) from (I), and
(2) a device consisting of a container (specifically an affinity column) containing (I) and having an inlet and an outlet for liquid.
USE - The method and device are useful for removing, recovering, purifying and/or concentrating (III) contained in liquid samples, specifically fractions contained in a mammalian body fluid or cell culture sample.
(III) is e.g. glycoprotein Ib, the glycoprotein in IIb/IIIa complex, collagen, factor VIII (including recombinant derivatives and analogues), vWF antigen, vWF antibody or an enzyme recognising vWF as substrate (e.g. vWF multimerase or vWF depolymerase).
Saccharides binding vWF (e.g. heparin) can also be isolated.
Typical applications are: isolation of pure proteins with **factor VIII activity** for biochemical-analytical, diagnostic or therapeutic use; purification of vWF multimerase; extra-corporeal immuno-adsorption of anti-vWF antibodies (associated with pathological states such as auto-immune disease); or preparative recovery of mono- or poly-clonal anti-vWF antibodies for diagnostic use.
ADVANTAGE - The affinity of (I) for (III) is higher than that of plasma vWF, so that (III) can be isolated even from solutions containing vWF (e.g. in **factor VIII-vWF complex**).
(III) can be isolated in high yield, specifically at least 80% (claimed). (I) have high stability, can be used repeatedly and retain the 'nativity' of vWF. r-vWF is readily available in high purity.
Dwg.0/2
ACCESSION NUMBER: 1998-348459 [30] WPIX
DOC. NO. CPI: C1998-107760
TITLE: Carrier-fixed recombinant von Willebrand factor derivative - useful for isolating proteins binding von Willebrand factor, e.g. factor VIII, in high yield.
DERWENT CLASS: B04 D16
INVENTOR(S): EIBL, J; SCHWARZ, H; TURECEK, P
PATENT ASSIGNEE(S): (IMMO) IMMUNO AG; (BAXT) BAXTER AG; (EIBL-I) EIBL J; (SCHW-I) SCHWARZ H; (TURE-I) TURECEK P
COUNTRY COUNT: 22
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 9825969	A1	19980618	(199830)*	GE	29
RW: AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE					
W: CZ HU JP US					
AT 9602178	A	19990315	(199916)		
AT 405740	B	19990915	(199942)		
CZ 9902112	A3	19990915	(199945)		
EP 954533	A1	19991110	(199952)	GE	
R: AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE					
HU 9903789	A2	20000328	(200025)		
JP 2001506987	W	20010529	(200136)		22
US 2002019036	A1	20020214	(200214)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 9825969	A1	WO 1997-AT253	19971119
AT 9602178	A	AT 1996-2178	19961213
AT 405740	B	AT 1996-2178	19961213
CZ 9902112	A3	WO 1997-AT253	19971119
		CZ 1999-2112	19971119
EP 954533	A1	EP 1997-913009	19971119
		WO 1997-AT253	19971119
HU 9903789	A2	WO 1997-AT253	19971119
		HU 1999-3789	19971119
JP 2001506987	W	WO 1997-AT253	19971119
		JP 1998-526003	19971119
US 2002019036	A1 Div ex	WO 1997-AT253	19971119
	Div ex	US 1999-319116	19990602
		US 2001-967937	20011002

FILING DETAILS:

PATENT NO	KIND		PATENT NO
AT 405740	B	Previous Publ.	AT 9602178
CZ 9902112	A3	Based on	WO 9825969
EP 954533	A1	Based on	WO 9825969
HU 9903789	A2	Based on	WO 9825969
JP 2001506987	W	Based on	WO 9825969

PRIORITY APPLN. INFO: AT 1996-2178 19961213

L4 ANSWER 29 OF 29 SCISEARCH COPYRIGHT (c) 2004 The Thomson Corporation. on STN

TI Factor VIII, von Willebrand factor and the risk of major ischaemic heart disease in the Caerphilly Heart Study

AB The relationships of three measurements of the factor VIII/von Willebrand factor (VWF) complex (**factor VIII activity**, FVIIIc (one-stage assay); VWF antigen, VWF Ag (ELISA); and VWF activity, VWF act, measured by a recently-developed ELISA) to major ischaemic heart disease (IHD) events were studied in 1997 men aged 49-65 years, in the second phase of the Caerphilly Heart Study. These variables were related using logistic regression analysis to myocardial infarction or IHD death, which occurred in 129 men during an average follow-up period of 61 months. All three measurements were highly correlated (r=0.63-0.77), and each was significantly associated with incident major IHD on univariate analyses (relative odds in highest fifth compared to lowest fifth, 1.68-1.90; P=0.028-0.006) and on multivariate analyses adjusting for major IHD risk factors and for baseline IHD. Neither FVIIIc nor VWF act was significantly related to incident IHD

following adjustment for VWF Ag. We therefore suggest that the associations between these three measurements of the **factor VIII/VWF complex** and incident IHD might have at least three explanations: VWF Ag is a marker of arterial endothelial disturbance; VWF act promotes platelet adhesion/aggregation and hence the platelet component of arterial thrombosis; and FVIIIc promotes fibrin formation and hence the fibrin component of arterial thrombosis.

ACCESSION NUMBER: 1999:358232 SCISEARCH
THE GENUINE ARTICLE: 192CP
TITLE: Factor VIII, von Willebrand factor and the risk of major ischaemic heart disease in the Caerphilly Heart Study
AUTHOR: Rumley A; Lowe G D O (Reprint); Sweetnam P M; Yarnell J W G; Ford R P
CORPORATE SOURCE: UNIV GLASGOW, GLASGOW ROYAL INFIRM, DEPT MED, 10 ALEXANDRA PARADE, GLASGOW G31 2ER, LANARK, SCOTLAND (Reprint); UNIV GLASGOW, GLASGOW ROYAL INFIRM, DEPT MED, GLASGOW G31 2ER, LANARK, SCOTLAND; LLANDOUGH HOSP, MRC, EPIDEMIOL UNIT S WALES, PENARTH, S GLAM, WALES; SHIELD DIAGNOST LTD, DUNDEE, SCOTLAND; QUEENS UNIV BELFAST, DIV EPIDEMIOL, BELFAST, ANTRIM, NORTH IRELAND
COUNTRY OF AUTHOR: SCOTLAND; WALES; NORTH IRELAND
SOURCE: BRITISH JOURNAL OF HAEMATOLOGY, (APR 1999) Vol. 105, No. 1, pp. 110-116.
Publisher: BLACKWELL SCIENCE LTD, P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND.
ISSN: 0007-1048.
DOCUMENT TYPE: Article; Journal
FILE SEGMENT: LIFE; CLIN
LANGUAGE: English
REFERENCE COUNT: 24